Let me tell you about an enzyme.This enzyme has a name. The name is going to look like a vehicle registration number. The name is CYP2C19. It lives in your liver. Most of the time, you do not think about it, because most of the time, your liver does not require your conscious attention — which is, in general, an excellent property for an organ to have.But CYP2C19 is doing one of the more important jobs in your entire body. It is taking medicines that you swallow — molecules that, in their original form, do absolutely nothing — and chemically rearranging them into the version of themselves that actually works. Most drugs you take are like a houseguest who arrives at your door in a sealed box. They are useless until your liver opens the box. CYP2C19 is the enzyme that opens the box.Now, here is where the story gets interesting. Some people’s CYP2C19 is excellent at opening boxes. Some people’s CYP2C19 is mediocre at opening boxes. Some people’s CYP2C19 is, frankly, terrible at opening boxes. Which one you are is determined by your genes, which were determined before you were born, which were determined long before anyone had a conversation about it with you.For most of medical history, this was a curiosity. Doctors noticed that the same medicine, at the same dose, seemed to work like magic on some patients and do absolutely nothing for others, and they shrugged and tried a different drug. They had no way to test why. They had no way to predict. They were, in effect, prescribing in the dark — though they were very good at it, because they had a few hundred years of clinical observation to lean on, and human bodies are, on average, more similar than they are different.Then, between roughly 1990 and 2010, two things happened more or less simultaneously. The cost of sequencing a human genome fell, in the space of about twenty years, from approximately three billion dollars to approximately three hundred dollars. (You read that correctly. Approximately. Three. Hundred. Dollars.) And separately, we built up a vast catalogue of which variations in which genes affected which biological processes — including, crucially, which variations in which genes affected which medicines.This new field — pharmacogenomics, which sounds intimidating but really just means “the study of how your genes affect how your body deals with medicines” — is one of the genuinely revolutionary developments in twenty-first-century medicine. It is also, awkwardly, one of the least well-known.Here is what we now know. Roughly half of all South Asians — including the largest study of British Bangladeshis and Pakistanis, where 57% of 44,000 people sampled fell into this group — are intermediate or poor metabolisers of CYP2C19. This means that one of the most commonly prescribed medications after a heart attack, clopidogrel, may be doing significantly less than the doctor prescribing it believes it is doing. The patient’s recurrent heart attack risk, in this group, is roughly three times higher than in efficient metabolisers.Roughly one-third of Indians carry at least one copy of a variant in the MTHFR gene that affects folate metabolism. If they are prescribed standard folic acid for, say, high homocysteine, they may not be converting it into the active form their body actually needs. They will look like the medicine isn’t working. The medicine, for their specific body, isn’t.A meaningful subset of the population carries variants in the SLCO1B1 gene that dramatically affect their tolerance for statins — the most prescribed cholesterol drug in the world. Some of these people develop muscle pain so severe they stop taking the drug. The doctor concludes the patient is “non-compliant.” The genuine answer is that the dose was wrong for the metabolism.And so on. There are hundreds of these. Some are clinically actionable today. Many will be clinically actionable in the next decade. The point is not that any one of them, on its own, is going to change your life. The point is that, taken together, they describe a fact about modern medicine: the standard prescription was never standard. It was an average. And you, the specific human standing in front of the doctor, are not an average.This is what tests like Mira One — and its peers in the Indian market: MedGenome’s panels, Strand’s offerings, Mapmygenome’s options — are quietly fixing. Not by replacing the doctor. By giving the doctor more information. By turning the conversation between you and the physician into a conversation about you, specifically, rather than a conversation about the average patient.Three things worth knowing about all of this, if you take nothing else away.One: your genome does not change. Sequence it once, and the information is yours for life. Every doctor you ever see, every medicine you are ever prescribed, every decision you ever make about your body has more signal in it if that information exists. It is the most durable health asset you can buy.Two: the test is not magic. It does not predict the future. It does not tell you when you will die or what you will die of. It gives you and your physician a sharper starting point. That is all. That is also, it turns out, a lot.Three: the test is expensive. ₹1 lakh, in the case of Mira One. Less, for some less comprehensive options. More, for some that include things you almost certainly don’t need yet. The right question is not “can I afford this?” The right question is: “will the information change a single decision I or my doctor make over the next thirty years?” If the answer is yes — and for most Indians over 35 with a family history of anything, the answer is straightforwardly yes — then the maths is simple.CYP2C19 is doing its job, right now, in your liver. So is MTHFR, and SLCO1B1, and a few hundred other enzymes whose names will probably never make for an interesting cocktail-party anecdote. They are doing their job slightly differently in you than in the person sitting next to you. For most of medical history, no one knew, and no one could find out. Now we can. That is the only thing that has changed.It is also, when you really think about it, one of the more important things to have changed.
